The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery
Launched by KASR EL AINI HOSPITAL · Mar 1, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how stopping certain heart medications, called Renin Angiotensin System (RAS) inhibitors, affects heart injury in patients undergoing major surgery for colorectal cancer. Researchers want to see if discontinuing these medications before and during surgery can impact heart health in these patients, who may be at risk for heart problems during and after their procedures.
To participate in this study, you must be over 18 years old and have a history of high blood pressure that has been managed with RAS inhibitors for at least three months. You should be scheduled for a major abdominal cancer surgery that will take more than two hours and requires a hospital stay of at least three days. If you join the trial, you will be monitored closely during your surgery and recovery to understand how stopping the medication affects your heart. It’s important to note that patients who have had a recent heart attack or have certain other medical conditions may not be eligible. This study is currently looking for volunteers, so if you think you might qualify, consider discussing it with your doctor.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Both sexes
- • ASA 2-3
- • Chronic hypertensive patients (\> 3 months before surgery) controlled on ACEIs or ARBs or combination therapy containing one of the RAS inhibitors.
- • Scheduled for major abdominal cancer surgery (surgery with an expected duration of \> 2 h from the surgical incision and a postoperative hospital stay of least three days).
- Exclusion Criteria:
- • Patient refusal.
- • Recent myocardial infarction (within 3 months).
- • Any condition, which in the opinion of the treating clinician, would result in the patient being harmed by the cessation of the ACE-I and/or ARB therapy.
- • Emergency surgery
About Kasr El Aini Hospital
Kasr El Aini Hospital, a prestigious medical institution affiliated with Cairo University, is dedicated to advancing healthcare through innovative clinical research. With a commitment to excellence, the hospital serves as a leading sponsor of clinical trials, leveraging its state-of-the-art facilities and a multidisciplinary team of healthcare professionals. The institution focuses on a diverse range of therapeutic areas, aiming to improve patient outcomes and contribute to the global medical community. By fostering collaboration and adhering to the highest ethical standards, Kasr El Aini Hospital plays a pivotal role in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported